Navigation Links
Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
Date:11/1/2010

HOBOKEN, N.J., Nov. 1, 2010 /PRNewswire/ -- Octapharma AG, one of the largest human protein products manufacturers in the world, and Octapharma USA today announced that patients diagnosed with severe hemophilia A have started treatment in a multi-center study that is researching the use of the first recombinant Factor VIII (rFVIII) derived from a human cell line (Human-cl rhFVIII). Researchers are investigating Human-cl rhFVIII, to assess pharmacokinetics, efficacy, safety and immunogenicity for previously treated patients with severe hemophilia A.

The National Institutes of Health estimate that 90 percent of all hemophilia patients have hemophilia A, also known as Factor VIII deficiency, and 70 percent of those have the severe form of the illness.

The prospective, randomized, actively controlled, open label Phase 2 trial is being held at research centers in the US and Germany under the title "Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of human-cl rhFVIII, a Newly Developed Human Cell-Line Derived Recombinant FVIII Concentrate in Previously Treated Patients with Severe Hemophilia A." The study started in spring 2010 and patient enrollment is well underway. Please visit www.clinicaltrials.gov for details.

Human-cl rhFVIII is a fourth-generation recombinant factor VIII (rFVIII) concentrate developed by Octapharma for the control and prevention of bleeding episodes and for surgical prophylaxis in patients with hemophilia A.  Human-cl rhFVIII is produced in genetically modified Human Embryonic Kidney (HEK) 293F cells. Human-cl rhFVIII is currently the only rFVIII, which has a human glycosylation pattern. Today, the development of antibodies against in
'/>"/>

SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
2. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
3. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
4. Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease
5. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
6. Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
7. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
8. FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USAs New Therapy for Common Inherited Bleeding Disorder
9. Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients
10. Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015 The saturated European ... from the rising incidence of preterm births. This trend ... care unit (NICU) devices but also skilled and trained ... from Frost & Sullivan, Analysis of the Western European ... revenues of $151.5 million in 2014 and estimates this ...
(Date:4/21/2015)... April 21, 2015 EUSA Pharma ... reach, today announced the appointment of Lee Morley ... as a Non-Executive Director.  Bryan Morton, who established EUSA ... Chairman.   Lee Morley joins ... President, Head of Commercial for Europe ...
(Date:4/21/2015)... April 21, 2015  Legal-Bay LLC, The Lawsuit ... Boehringer Ingelheim Pharmaceuticals, is seeking FDA approval for ... According to PBR, Boehringer submitted a supplemental new ... that Pradaxa will be approved for the prophylaxis ... (PE) for patients who have undergone a primary ...
Breaking Medicine Technology:Rising Numbers of Preterm Births Stoke Demand for Infant Care Solutions in Europe 2Rising Numbers of Preterm Births Stoke Demand for Infant Care Solutions in Europe 3EUSA Pharma Appoints Lee Morley as Chief Executive and Industry Veteran Göran Ando to Board of Directors 2EUSA Pharma Appoints Lee Morley as Chief Executive and Industry Veteran Göran Ando to Board of Directors 3Pradaxa Maker Boehringer Ingelheim Pharmaceuticals Pursues Pradaxa FDA Approval to treat DVT and PE 2Pradaxa Maker Boehringer Ingelheim Pharmaceuticals Pursues Pradaxa FDA Approval to treat DVT and PE 3
... SARcode Corporation presented data today for their lead investigational ... trial, subjects receiving SAR 1118 demonstrated a reduction in ... as compared to placebo. These data were part of ... Vision and Ophthalmology (ARVO) Annual Meeting held in Fort ...
... 3, 2011 At the Board of Directors meeting held ... per share. The dividend is payable on June 15, 2011 ... About Sigma-Aldrich: Sigma-Aldrich is a leading ... to Improve the Quality of Life. Its chemical and biochemical ...
Cached Medicine Technology:SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease 2SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease 3
(Date:4/21/2015)... United Benefit Advisors (UBA), the nation’s ... to welcome Power Kunkle Benefits Consulting as its ... Jeff Power have been committed to providing the ... more than 450 clients. For Power Kunkle Benefits ... stewardship, ethical consulting, and measurable results. , ...
(Date:4/21/2015)... 2015 Atlantic Information Services, Inc. ... Medicare-Medicaid Dual Eligibles Database, a brand-new, continually updated ... to the more than 9 million Medicare-Medicaid dual ... than $300 billion in annual health care spending. ... team that also creates the industry-leading AIS’s Directory ...
(Date:4/21/2015)... Nashville, Tenn. – Radsource, a leader ... Archiving and Communication Systems (PACS), has expanded its ... the first quarter of 2015. , Kentucky Breast ... and Lowcountry Orthopaedics & Sports Medicine (Charleston, SC) ... services. Mt. San Rafael Hospital (Trinidad, CO) will ...
(Date:4/21/2015)... eSight is the only technology in the world that ... Tuesday, May 5th, Low Vision Specialists of Maryland and ... an unveiling and demonstration of the technology at 8:30 a.m ... will be the first ophthalmic practice in Maryland to offer ... will be available on the day of the unveiling. , ...
(Date:4/21/2015)... 2015 With a growing number of ... Worldwide indicates that international political instability and terrorism top ... survey by Clements, a global insurance provider with 68 ... their country of citizenship, also found strong concern but ... health care insurance overseas . , Asked to choose ...
Breaking Medicine News(10 mins):Health News:Power Kunkle Benefits Consulting Is the Latest Partner Firm To Join United Benefit Advisors 2Health News:New AIS Database Tracks All Programs, Plans Serving the Dual-Eligible Community 2Health News:Radsource Adds 4 ProtonPACS Clients in 1st Quarter 2Health News:eSight Electronic Glasses That Enable The Legally Blind To See – First In The World – Coming To Maryland 2Health News:eSight Electronic Glasses That Enable The Legally Blind To See – First In The World – Coming To Maryland 3Health News:Potential Expatriate Retirees Fear Political Violence, International Health Insurance Coverage 2Health News:Potential Expatriate Retirees Fear Political Violence, International Health Insurance Coverage 3
... types of blood pressures -- systolic pressure is created by ... the vessels and diastolic pressure is when the heart is ... is 120/80. The first number in a blood pressure reading ... is the diastolic pressure. ,A recent study shows ...
... According to a recent study conducted researchers suggest that ... from // having their tonsils and adenoids out. ... States. Most of the time, it is performed to ... however, doctors have also used the surgery to treat ...
... of hospitalization among people 65 or older but is ... heart damage or complications and the costs of care. ... test for high levels of the peptide in patients ... have congestive heart failure, in which the heart stops ...
... cancer in the United States. According to a recent study ... In addition, soy protein may help minimize the number and ... diets to female mice and followed their progress for one ... specific ingredients. Diet one contained milk protein, and diet two ...
... Previous studies show conflicting results over whether hormone replacement ... A recent study examines the pros and cons of ... combined HRT therapy for five years. All the women ... had menopausal symptoms, while others did not.Results show women ...
... with 32,800 middle-aged women has shown that there may be ... no risk factors whose blood has high amounts of iron.// ... in 1989-90 from women with no history of diabetes, cardiovascular ... had shown an average iron concentration of 109 nanograms/milliliter manifested ...
Cached Medicine News:Health News:Study On Self Measurement Of Blood Pressure 2Health News:‘Protein’ Produced By Overstressed Heart Muscle a Strong Indicator Of Heart Disea 2
9 mm slightly curved blade. Hexagonal handle....
9 mm blade....
4 mm disposable bevel blade. Malleable shafts. Flat spot on handle designed to guide knife in perforation....
Storz Ear Knife Handle....
Medicine Products: